260 related articles for article (PubMed ID: 28900272)
1. From malaria to cancer: Computational drug repositioning of amodiaquine using PLIP interaction patterns.
Salentin S; Adasme MF; Heinrich JC; Haupt VJ; Daminelli S; Zhang Y; Schroeder M
Sci Rep; 2017 Sep; 7(1):11401. PubMed ID: 28900272
[TBL] [Abstract][Full Text] [Related]
2. New HSP27 inhibitors efficiently suppress drug resistance development in cancer cells.
Heinrich JC; Donakonda S; Haupt VJ; Lennig P; Zhang Y; Schroeder M
Oncotarget; 2016 Oct; 7(42):68156-68169. PubMed ID: 27626687
[TBL] [Abstract][Full Text] [Related]
3. Implementation of a Pipeline Using Disease-Disease Associations for Computational Drug Repurposing.
Balasundaram P; Kanagavelu R; James N; Maiti S; Veerappapillai S; Karuppaswamy R
Methods Mol Biol; 2019; 1903():129-148. PubMed ID: 30547440
[TBL] [Abstract][Full Text] [Related]
4. The antimalarial drug amodiaquine possesses anti-ZIKA virus activities.
Han Y; Mesplède T; Xu H; Quan Y; Wainberg MA
J Med Virol; 2018 May; 90(5):796-802. PubMed ID: 29315671
[TBL] [Abstract][Full Text] [Related]
5. Computational Cell Cycle Profiling of Cancer Cells for Prioritizing FDA-Approved Drugs with Repurposing Potential.
Lo YC; Senese S; France B; Gholkar AA; Damoiseaux R; Torres JZ
Sci Rep; 2017 Sep; 7(1):11261. PubMed ID: 28900159
[TBL] [Abstract][Full Text] [Related]
6. A network based approach to drug repositioning identifies plausible candidates for breast cancer and prostate cancer.
Chen HR; Sherr DH; Hu Z; DeLisi C
BMC Med Genomics; 2016 Jul; 9(1):51. PubMed ID: 27475327
[TBL] [Abstract][Full Text] [Related]
7. Pathway-Based Drug Repositioning for Cancers: Computational Prediction and Experimental Validation.
Iwata M; Hirose L; Kohara H; Liao J; Sawada R; Akiyoshi S; Tani K; Yamanishi Y
J Med Chem; 2018 Nov; 61(21):9583-9595. PubMed ID: 30371064
[TBL] [Abstract][Full Text] [Related]
8. Predicting new indications for approved drugs using a proteochemometric method.
Dakshanamurthy S; Issa NT; Assefnia S; Seshasayee A; Peters OJ; Madhavan S; Uren A; Brown ML; Byers SW
J Med Chem; 2012 Aug; 55(15):6832-48. PubMed ID: 22780961
[TBL] [Abstract][Full Text] [Related]
9. Exploring Amodiaquine's Repurposing Potential in Breast Cancer Treatment-Assessment of In-Vitro Efficacy & Mechanism of Action.
Parvathaneni V; Chilamakuri R; Kulkarni NS; Baig NF; Agarwal S; Gupta V
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232751
[TBL] [Abstract][Full Text] [Related]
10. Computational drug repositioning for cancer therapeutics.
Jiao M; Liu G; Xue Y; Ding C
Curr Top Med Chem; 2015; 15(8):767-75. PubMed ID: 25732789
[TBL] [Abstract][Full Text] [Related]
11. Hit identification of novel heparanase inhibitors by structure- and ligand-based approaches.
Gozalbes R; Mosulén S; Ortí L; Rodríguez-Díaz J; Carbajo RJ; Melnyk P; Pineda-Lucena A
Bioorg Med Chem; 2013 Apr; 21(7):1944-51. PubMed ID: 23415087
[TBL] [Abstract][Full Text] [Related]
12. Predicting Potential Drugs for Breast Cancer based on miRNA and Tissue Specificity.
Yu L; Zhao J; Gao L
Int J Biol Sci; 2018; 14(8):971-982. PubMed ID: 29989066
[TBL] [Abstract][Full Text] [Related]
13. Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent drug candidates for cancer treatment.
Nagaraj AB; Wang QQ; Joseph P; Zheng C; Chen Y; Kovalenko O; Singh S; Armstrong A; Resnick K; Zanotti K; Waggoner S; Xu R; DiFeo A
Oncogene; 2018 Jan; 37(3):403-414. PubMed ID: 28967908
[TBL] [Abstract][Full Text] [Related]
14. Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compounds.
Carrella D; Manni I; Tumaini B; Dattilo R; Papaccio F; Mutarelli M; Sirci F; Amoreo CA; Mottolese M; Iezzi M; Ciolli L; Aria V; Bosotti R; Isacchi A; Loreni F; Bardelli A; Avvedimento VE; di Bernardo D; Cardone L
Oncotarget; 2016 Sep; 7(37):58743-58758. PubMed ID: 27542212
[TBL] [Abstract][Full Text] [Related]
15. Could the FDA-approved anti-HIV PR inhibitors be promising anticancer agents? An answer from enhanced docking approach and molecular dynamics analyses.
Arodola OA; Soliman ME
Drug Des Devel Ther; 2015; 9():6055-65. PubMed ID: 26622167
[TBL] [Abstract][Full Text] [Related]
16. Discovery of Novel Liver-Stage Antimalarials through Quantum Similarity.
Sullivan DJ; Liu Y; Mott BT; Kaludov N; Martinov MN
PLoS One; 2015; 10(5):e0125593. PubMed ID: 25951139
[TBL] [Abstract][Full Text] [Related]
17. Drug Repositioning to Accelerate Drug Development Using Social Media Data: Computational Study on Parkinson Disease.
Zhao M; Yang CC
J Med Internet Res; 2018 Oct; 20(10):e271. PubMed ID: 30309833
[TBL] [Abstract][Full Text] [Related]
18. Molecular epidemiology of malaria in cameroon. IX. Characteristics of recrudescent and persistent Plasmodium falciparum infections after chloroquine or amodiaquine treatment in children.
Basco LK; Ndounga M; Keundjian A; Ringwald P
Am J Trop Med Hyg; 2002 Feb; 66(2):117-23. PubMed ID: 12135279
[TBL] [Abstract][Full Text] [Related]
19. Recommendation Techniques for Drug-Target Interaction Prediction and Drug Repositioning.
Alaimo S; Giugno R; Pulvirenti A
Methods Mol Biol; 2016; 1415():441-62. PubMed ID: 27115647
[TBL] [Abstract][Full Text] [Related]
20. Novel drug candidate for the treatment of several soft‑tissue sarcoma histologic subtypes: A computational method using survival‑associated gene signatures for drug repurposing.
Yang X; Huang WT; Wu HY; He RQ; Ma J; Liu AG; Chen G
Oncol Rep; 2019 Apr; 41(4):2241-2253. PubMed ID: 30816547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
